Solana Beach, CA, United States of America

Bernhard Hubert Geierstanger

This inventor holds 20 USPTO granted patents and 13 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Antibody Drug Conjugates. Top assignees: Novartis Ag, Irm LLC, Other. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bernhard Hubert Geierstanger. Retrieved from https://idiyas.com/inventor/bernhard-hubert-geierstanger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 13)

% Patents Active = 80.0

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 5 (Patent Applications = 14)

Average Co-Inventor Count = 7.2

ph-index = 3

Forward Citations = 51(Granted Patents)

Location History:

Solana Beach, CA (US) (2014 - 2023)
San Diego, CA (US) (2017 - 2023)

Company Filing History:

1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Antibody Drug Conjugates

Cytotoxic Peptides

Immunoconjugates

CKIT

CCR7

Fibroblast Growth Factor 21

Site-Specific Modifications

Chemical Derivatization

Immunoregulation

Ablation

Toll-Like Receptor Agonist

Engrafted Compositions

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180291 - Anti-CCR7 antibody drug conjugates (2024-12-31),

2. 12171839 - Antibody drug conjugates for ablating hematopoietic stem cells (2024-12-24),

3. 11833215 - CKIT antibody drug conjugates (2023-12-05),

4. 11634497 - Anti-CCR7 antibody drug conjugates (2023-04-25),

5. 11596695 - Specific sites for modifying antibodies to make immunoconjugates (2023-03-07),

6. 11357864 - Antibody drug conjugates for ablating hematopoietic stem cells (2022-06-14),

7. 11136366 - Methods of treating immune related disorders using antibody-cytokine engrafted compositions (2021-10-05),

8. 10973826 - Antibody conjugates comprising toll-like receptor agonist (2021-04-13),

9. 10787480 - Cytotoxic peptides and conjugates thereof (2020-09-29),

10. 10786578 - CKIT antibody drug conjugates (2020-09-29),

11. 10669323 - Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins (2020-06-02),

12. 10392421 - Cytotoxic peptides and conjugates thereof (2019-08-27),

13. 10280139 - Cytotoxic peptides and conjugates thereof (2019-05-07),

14. 10144768 - Antibody cytokine engrafted compositions and methods of use for immunoregulation (2018-12-04),

15. 9988420 - Cytotoxic peptides and conjugates thereof (2018-06-05),

Title: **Bernhard Hubert Geierstanger: Innovator in Biotechnology**

Introduction

Bernhard Hubert Geierstanger, based in Solana Beach, CA, has made significant contributions to the field of biotechnology with an impressive portfolio of 20 patents. His innovations primarily focus on developing new therapeutic approaches, particularly in cancer treatment.

Latest Patents

Among his notable inventions are the anti-CCR7 antibody drug conjugates, which disclose novel antibodies, antigen binding fragments, and methods for treating or preventing cancer. These advancements also encompass diagnostic applications utilizing the disclosed antibodies. Another significant patent is for antibody drug conjugates designed for ablating hematopoietic stem cells, which involve a specific binding to human cKIT, presenting new avenues for treating patients in need.

Career Highlights

Geierstanger has had an impactful career with reputable companies like Novartis AG and Irm LLC. His work at these organizations has allowed him to push the boundaries of current medical treatments and contribute to pharmaceutical development.

Collaborations

Throughout his journey, he has collaborated with esteemed colleagues, including Tetsuo Uno and Weijia Ou, which has enriched the research environment and led to groundbreaking advancements in their field.

Conclusion

Bernhard Hubert Geierstanger stands out as an inventive force in biotechnology with a dedication to addressing complex health issues through innovative approaches. His ongoing contributions continue to pave the way for future developments in cancer therapeutics and diagnostics.

Profile summary based on public USPTO records.